InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,050.61
(
-0.39%
)
US TECH 100
21,405.20
(
-0.56%
)
Dow Jones
43,449.90
(
-0.61%
)
Brent Oil
73.01
(
-0.13%
)
Bitcoin
103,546.73
(
-2.45%
)
Post# of 467
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Whalatane

Send PM Follow Ignore
Followers 129
Posts 21455
Boards Moderated 0
Alias Born 06/13/2011

Whalatane

Member Level

Re: rosemountbomber post# 461

Thursday, 05/30/2024 2:47:47 PM

Thursday, May 30, 2024 2:47:47 PM

Post# of 467

Regulus is currently dosing patients in the third cohort of the MAD study patients with either 3mg/kg of RGLS8429 or a placebo every other week for three months. Enrolment in this cohort has been completed and top-line data from the same is expected in mid-2024.



That was March 13th .......So by June 13th the 3 mth dosing is over ...small number so data a week or 2 later ??
Kiwi
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent RGLS News
More RGLS News
InvestorsHub NewsWire

UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM

Avant Technologies and Ainnova Secure Advanced AI Algorithms for Early Detection of Four Additional Diseases in the U.S. • AVAI • Dec 17, 2024 8:00 AM

North Bay Resources Announces MET Results of 97% Gold Recovery with Upgrade to 11.2 Ounces per Ton Concentrate, Fran Gold Project; Completes 120 Ton Winter Ore Shipment • NBRI • Dec 16, 2024 9:00 AM

Mass Megawatts Announces the Financial Reporting Status Being Current as of Today • MMMW • Dec 16, 2024 8:18 AM

VAYK Renewed JV to Renovate Historic Landmark into "Most Sought-after Airbnb Place" in Downtown Atlanta • VAYK • Dec 12, 2024 9:36 AM

Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN • SLXN • Dec 11, 2024 9:22 AM

Start posting your company's news
Only $200 per official company press release!